

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 01D1089574	(X3) Date Survey Completed 04/11/2022
Name of Provider or Supplier Affinity Physicians Services	Street Address, City, State 5890 Valley Road Suite 200, Birmingham, AL	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on reviews of the CMS (Centers for Medicare and Medicaid Services) CASPER reports and MLE (Medical Laboratory Evaluation) Proficiency Testing evaluations, the laboratory failed the WBC Differential (White Blood Cell Differential) for two consecutive testing events, Event #3, 2021 and Event #1, 2022. These failures resulted in an initial unsuccessful participation. The findings include: 1. Refer to D2130.</p>
D2130	<p>HEMATOLOGY CFR(s): 493.851(f)</p>

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on reviews of the CMS (Centers for Medicare and Medicaid Services) CASPER reports and MLE (Medical Laboratory Evaluation) Proficiency Testing evaluations, the laboratory failed the WBC Differential (White Blood Cell Differential) for two consecutive testing events, Event #3, 2021 and Event #1, 2022. These consecutive failures resulted in an initial unsuccessful participation. The findings include: 1. A review of the CASPER reports revealed the laboratory scored 73 % for the WBC Differential for Event #3, 2021 and 46 % for Event #1, 2022 (unsatisfactory performances). 2. The MLE evaluations confirmed the above noted findings.